Recombinant Mouse TGF-beta RIII Protein, CF

Name: Recombinant Mouse TGF-beta RIII Protein, CF
Brand: R&D Systems
SKU: 5034-R3
Price: 516 USD
Availability: InStock

R&D Systems | Catalog # 5034-R3

Submit a review

Citations (2)

Product Documents

100% Guarantee

Product Specifications
Preparation & Storage
Calculators
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

R&D Systems NS0-derived Recombinant Mouse TGF-beta RIII Protein (5034-R3)
Quality control testing to verify active proteins with lot specific assays by in-house scientists
All R&D Systems proteins are covered with a 100% guarantee

Source

NS0

Accession Number

NP_035708

Applications

Bioactivity

View all TGF-beta RIII Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived mouse TGF-beta RIII protein
Gly23-Thr785, with a C-terminal 6-His tag

Purity

>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Gly23

Predicted Molecular Mass

85.6 kDa

SDS-PAGE

105-115 kDa, reducing conditions

Activity

Measured by its ability to inhibit TGF-beta 2 activity on HT‑2 mouse T cells. Tsang, M. et al. (1995) Cytokine 7:389.
The ED₅₀ for this effect is 8-40 ng/mL in the presence of 1 ng/mL of rhTGF-beta 2.

Formulation, Preparation, and Storage

5034-R3

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 100 μg/mL in sterile PBS. Loading...
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Background: TGF-beta RIII

Transforming growth factor beta receptor III (TGF-beta RIII; also betaglycan) is a ubiquitously expressed, 280 kDa type I transmembrane proteoglycan member of the TGF-beta superfamily of proteins (1). Mouse TGF-beta RIII is synthesized as an 850 amino acid (aa) precursor that consists of a 22 aa signal sequence, a 763 extracellular domain (ECD), a 23 aa transmembrane region, and a 42 aa cytoplasmic tail (SwissProt # O88393). The large ECD contains heparan sulfate and chondroitin sulfate glycosaminoglycans, five potential N-linked glycosylation sites, and a zona pellucida-like domain from residues 454 - 731 (1 - 2). The short cytoplasmic domain is rich in serine and threonine, but has no discernible signaling structure typical of receptor kinases (2). Proteolysis at one of two potential juxtamembrane cleavage sites (Lys743Lys and Leu750AlaValVal) allows cells to release TGF-beta RIII in a soluble form (1 - 2). Mouse TGF beta RIII shares 94%, 82%, 80%, and 67% aa sequence identity with rat, human, porcine, and chicken TGF-beta RIII, respectively (2). In all of these species, TGF beta RIII contains 17 cysteines that are 100% conserved (2). TGF-beta RIII binds with high affinity to TGF-beta 1, TGF-beta 2, and TGF-beta 3 isoforms (1). TGF-beta RIII functions by binding, and then "presenting" ligand to TGF-beta type II receptors (1, 3). It also functions to limit ligand availability to the receptor via proteolysis which releases the soluble form of TGF beta RIII along with any bound factors, making them inaccessible to cell-surface receptors (1, 3). TGF-beta RIII can therefore enhance or inhibit cell signaling. TGF-beta RIII has been shown to play an essential role in the formation of the atrioventricular cushion and coronary vessels during development of the heart (4 - 6). TGF beta RIII also plays a role in many cancers. Increased expression of TGF beta RIII is found in higher grade lymphomas, and reduced expression of TGF beta RIII is found with advanced stage neuroblastomas and ovarian carcinomas (4, 7 - 9). Low TGF-beta RIII expression also correlates with higher grade among a cohort of breast cancers (4, 10). Additionally, overexpression of TGF-beta RIII in MDA-231 human breast cancer cells and DU145 prostate cancer cells results in decreased tumor invasion in vitro and in vivo (4, 11 - 12).